Chikujee is focused on developing therapeutic target specific multifunctional nanobindi to capitalize on the enormous opportunity to improve on currently marketed blockbuster drugs or enable the delivery of novel classes of therapeutics.  Our proprietary product engine is focused on improving the efficacy and expanding the applicability of existing blockbuster drugs.  We anticipate our first product entering the clinic in 2009.

Chikujee Therapeutics has chosen to work initially on building its pipeline with marketed blockbuster compounds that have been known for their undesirable side effects. The Company has four internal drug delivery engines funded through internal and grant support:

 BindiPR^TM,  a controlled release delivery vehicle for target specific delivery of protein based therapeutics to produce a more effective drug for treatment with minimal side effects.

 BindiNA^TM, a controlled release delivery vehicle for target specific delivery of nucleic acid based therapeutics, RNAi, Oligos, gene therapy vectors etc., to provide effective disease specific treatment with minimal side effects.

 BindiSM^TM for the cell specific delivery of small molecules like chemotherapy agents to the target site

 BindiGP^TM a cell specific delivery of general purpose therapeutic agents to target tissues.

Drug Development Strategy:  Next Generation blockbusters

Multi-directional approach for creating next generation blockbusters

Generics to Brand ·     

       Example CT-101:  TSDV™-ENCAPSULATED PACLITAXEL ($ 1.8 Billion)

Life Cycle Extension· 

       Example CT-201:  TSDV™-ENCAPSULATED DOCETAXEL ($ 3 Billion)

New Drugs by IP unlocking ·

        Example CT-501:  TSDV™- ENCAPSULATED CAMPTOTHECIN ($ ?? Billion)·
        Example CT-601:  TSDV™- ENCAPSULATED Epothilone ($ ?? Billion)